The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 12, 2007, Pages 826-831

  Yeh, Ting Chi ^a,b   Liu, Hsi Che ^a   Wang, Lin Yen ^a   Chen, Shu Huey ^a   Lin, Wei Ying ^a   Liang, Der Cherng ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

Author keywords

Acute myeloid leukemia; Acute promyelocytic leukemia; Outcome; Protocol design; Treatment

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; LACTATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; FACTORIAL ANALYSIS; FEMALE; HUMAN; INFANT; MALE; MYCOSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; STEM CELL TRANSPLANTATION; TAIWAN; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; SURVIVAL RATE; SURVIVORS; TAIWAN; TRETINOIN;

EID: 37349104605     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31815a05aa     Document Type: Article

References (25)

1. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58:1203-1212.
2. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
3. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol. 1993;11:538-545.
4. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94:3015-3021.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
6. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460-462.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haemetol. 1991;78:325-329.
8. Liang D-C, Shih L-Y, Yang C-P, et al. Molecular analysis of fusion transcripts in childhood acute myeloid leukemia in Taiwan. Med Pediatr Oncol. 2001;37:555-556.
9. Liang D-C, Chang T-T, Lin K-H, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia. 2006;20:136-141.
10. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19:2025-2029.
11. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520.
12. Schiller G, Gajewski J, Mimers S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br J Haemetol. 1992;81:170.
13. Stasi R, Venditti A, Del Poeta G, et al. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Leukemia Res. 1996;20:535-549.
14. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666.
15. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group. J Clin Oncol. 1992;10:1103.
16. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313.
17. Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985;3:1583-1589.
18. Hiddenmann W, Aul C, Maschmeyer G, et al. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. Sem Hematol. 1991;28(suppl 4):35-38.
19. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998;101:130-140.
20. Uden AM, Brenning G, Engstedt L, et al. L-asparaginase and prednisolone pretreatment followed by rubidomycin and cytosine arabinoside for induction of remission in adult patients with acute myeloblastic leukaemia. Scand J Haematol. 1975;15:72-80.
21. Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210-1219.
22. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302-2309.
23. Forestier E, Heim S, Blennow E, et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haemetol. 2003;121:566-577.
24. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94:3707-3716.
25. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group - Report of three consecutive trials. Leukemia. 2005;19:2090-2100.